Danaher Corporation (DHR)
Danaher: Self-Inflicted Pessimism?
Danaher Corp. has faced market punishment recently, but maintains strong margins and impressive FCF despite a tough year, indicating resilience and potential for future growth. The company's strategic capital allocation, including share buybacks and acquisitions, suggests management is positioning for long-term value creation, despite short-term pessimism. Danaher's bioprocessing segment shows consistent growth, and the upcoming patent cliff is expected to provide significant tailwinds, boosting demand for their life science equipment.
Danaher Analysts Cut Their Forecasts After Downbeat Earnings
Danaher Corporation DHR reported weaker-than-expected fourth-quarter earnings on Wednesday.
Danaher Q4 Earnings Miss Estimates, Life Sciences Sales Rise Y/Y
DHR's fourth-quarter sales increase 2.1% year over year, benefiting from the solid performance of its Life Sciences and Biotechnology segments.
Danaher (DHR) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Danaher Corporation (DHR) Q4 2024 Earnings Call Transcript
Danaher Corporation (DHR) Q4 2024 Earnings Call Transcript
Danaher (DHR) Lags Q4 Earnings Estimates
Danaher (DHR) came out with quarterly earnings of $2.14 per share, missing the Zacks Consensus Estimate of $2.17 per share. This compares to earnings of $2.09 per share a year ago.
Danaher misses quarterly profit estimates on weak biotech demand
Danaher on Wednesday missed Wall Street estimates for fourth-quarter profit due to soft demand for tools and services used in drug development by its biotech and pharmaceutical clients.
Danaher Gears Up to Post Q4 Earnings: What Lies Ahead for the Stock?
DHR's Q4 results are likely to be ailed by weakness in the Biotechnology and Life Sciences segments.
Danaher (DHR) Earnings Expected to Grow: Should You Buy?
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Danaher: Transition Year Recap
Danaher faced a disappointing 2024, despite beating Q3 expectations, due to unaltered full-year guidance and a significant asset writedown. The company executed a $4.5 billion share buyback, with an additional 20 million shares authorized, reflecting confidence in long-term growth. Danaher's ROIC appears low due to heavy R&D and capex investments, but this expands its competitive moat and deters new entrants.
Danaher Corporation (DHR) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Danaher Corporation (NYSE:DHR ) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2024 2:15 PM ET Company Participants Rainer Blair - President and Chief Executive Officer Conference Call Participants Rachel Vatnsdal - J.P.
Danaher: A Wide-Moat Gem I Cannot Buy Enough Of
Danaher boasts a wide-moat business model with mission-critical products and recurring revenue streams, ensuring a durable competitive advantage and long-term growth potential. The company's disciplined M&A strategy and integration capabilities have driven significant value creation, supported by strong secular healthcare trends and a focus on innovation. Despite a modest 0.5% dividend yield, Danaher's 12.4% five-year CAGR and low payout ratio offer substantial growth potential for total return investors.
